Open access peer-reviewed chapter

Clinical and Biochemical Features of Patients with CYP24A1 Mutations

By Fay Joanne Hill and John A. Sayer

Submitted: November 7th 2015Reviewed: June 6th 2016Published: April 12th 2017

DOI: 10.5772/64503

Downloaded: 860

Abstract

The CYP24A1 gene encodes 1,25-hydroxyvitamin-D3-24-hydroxylase, a key enzyme responsible for the catabolism of active vitamin D (1,25-dihydroxyvitamin D3). Loss-of-function mutations in CYP24A1 lead to increased levels of active vitamin D metabolites. Clinically, two distinct phenotypes have been recognised from this: infants with CYP24A1 mutations present with infantile idiopathic hypercalcaemia, often precipitated by prophylactic vitamin D supplementation. A separate phenotype of nephrolithiasis, hypercalciuria and nephrocalcinosis often presents in adulthood. CYP24A1 mutations should be suspected when a classical biochemical profile of high active vitamin D metabolites, high or normal serum calcium, high urine calcium and low parathyroid hormone is detected. Successful treatment with fluconazole, a P450 enzyme inhibitor, has been shown to be effective in individuals with CYP24A1 mutations. Although CYP24A1 mutations are rare, early recognition can prompt definitive diagnosis and ensure treatment is commenced.

Keywords

  • CYP24A1
  • vitamin D
  • hypercalcaemia
  • idiopathic infantile hypercalcaemia
  • nephrolithiasis

1. Introduction

The supplementation of formula milk with vitamin D3 (cholecalciferol) prompted a rise in infants presenting with symptomatic hypercalcaemia in the United Kingdom during the 1950s [1]. While this public health initiative was proving highly successful in preventing rickets, for the small cohort of infants presenting with failure to thrive, dehydration and nephrocalcinosis, the consequences of their hypercalcaemia were at times fatal. A diagnosis of idiopathic infantile hypercalcaemia was given to many in this cohort. The apparent increased susceptibility of this minority group to vitamin D toxicity prompted research into a genetic predisposition. Fifty-nine years later, CYP24A1 mutations were identified demonstrating loss-of-function mutations encoding 1,25-hydroxyvitamin D3 24-hydroxylase, an enzyme with a key role in vitamin D metabolism [2].

More recently, CYP24A1 mutations have been recognised in an adult population of patients presenting with calcium-containing renal stones. On investigation, these patients typically displayed hypercalciuria, nephrocalcinosis and occasionally chronic kidney impairment. Vitamin D supplementation was not a feature in all cases [3], demonstrating a clinically significant phenotype manifesting from normal dietary vitamin D intake. Importantly, some patients had been symptomatic for many years, undergoing extensive investigations before a diagnosis was made. A continuing focus on preventative medicine, including oral vitamin D supplementation for maintenance of bone health and during pregnancy, is likely to continue to risk triggering manifestations of vitamin D toxicity in individuals carrying biallelic mutations in CYP24A1. As diagnostic tests and successful treatments are starting to emerge, it is important to recognise clinical presentations which should prompt screening for CYP24A1 deficiency [46].

2. CYP24A1 and the vitamin D pathway

The crucial role of vitamin D in calcium and phosphate homeostasis means excessive levels of its active form can precipitate symptomatic hypercalcaemia. The activation of vitamin D takes place in two stages. The first stage takes place in the liver: vitamin D3 is converted to 25-hydroxyvitamin D3, a reaction catalysed by 25-hydroxylase (CYP2R1). The second stage occurs in the kidney, when 25-hydroxyvitamin D3 is hydroxylated to 1,25-dihydroxyvitamin D3, the active form. This stage is catalysed by 1α-hydroxylase, an enzyme encoded by the CYP27B1 [2].

Figure 1.

Vitamin D metabolism pathway. Activation of Vitamin D: 1. Stage 1 occurs in the liver. Vitamin D3 is converted to 25-hydroxyvitamin D3 by the enzyme 25-hydroxylase. The CYP2R1 gene encodes 25-hydroxylase. 2. Stage 2 occurs in the kidney. 25-hydroxyvitamin D3 is converted to 1,25-dihydroxyvitamin D3 by the enzyme 1α-hydroxylase. The CYP27B1 gene encodes 1α-hydroxylase. 1,25-dihydroxyvitamin D3 is the physiologically most active form of vitamin D3 which binds to the vitamin D receptor. Inactivation of Vitamin D: Several hydroxylation steps occur in the catabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. The first of these steps is catalysed by the enzyme 1,25-hydroxyvitamin-D3-24-hydroxylase, which is encoded by the CYP24A1 gene.

The inactivation of vitamin D metabolites relies upon two pathways which both include steps catalysed by 1,25-hydroxyvitamin-D3-24-hydroxylase; CYP24A1 encodes this mitochondrial enzyme which is part of the cytochrome P450 system [6]. The enzyme is present in vitamin D target cells, predominantly located in the intestine and kidneys (Figure 1) [5].

2.1. Phenotypes

2.1.1. Idiopathic infantile hypercalcaemia

The first recognised phenotype of CYP24A1 mutations was in infants diagnosed with idiopathic infantile hypercalcaemia. These individuals presented with vomiting, dehydration, fevers and failure to thrive. On investigation, a typical biochemical profile of high serum calcium and suppressed parathyroid hormone levels emerged. Renal ultrasound often demonstrated nephrocalcinosis, deposition of calcium salts within the kidney. It was not initially known whether the underlying pathophysiology of idiopathic infantile hypercalcaemia (IIH) was due to excess production of vitamin D metabolites, or an inability to inactivate vitamin D. A candidate gene approach was used to investigate families with typical presentations of idiopathic infantile hypercalcaemia. This research revealed a recessive loss-of-function mutation, in which patients with CYP24A1 mutations were unable to inactivate vitamin D as they were deficient in the enzyme catalysing this pathway (1,25-hydroxyvitamin-D3-24-hydroxylase). Affected children presented either after sustained low-dose vitamin D prophylaxis or directly following bolus doses of vitamin D. One sibling in which vitamin D prophylaxis was avoided was proven to carry the same mutation but had remained clinically silent. This supported evidence directly linking exogenous vitamin D supplementation with precipitation of symptomatic hypercalcaemia [2].

2.1.2. Adult nephrolithiasis

Hypercalciuria is the most common cause of calcium-containing kidney stones. The recognition that 40–45% of patients with idiopathic hypercalciuria have at least one relative with nephrolithiasis implicates a genetic predisposition in many cases [4]. CYP24A1 mutations have now been proven in a cohort of adults presenting with nephrolithiasis, hypercalciuria, nephrocalcinosis and intermittent hypercalcaemia [4]. These patients had undergone extensive investigations before the cause of their nephrolithiasis was known, and multiple stone episodes and nephrocalcinosis may lead to progressive chronic kidney disease (CKD) [7]. This is important in highlighting the potential clinical spectrum of the phenotype, which may manifest without the trigger of vitamin D exposure. A typical biochemistry profile was found within this phenotype group, with normal/high serum calcium levels, suppressed parathyroid hormone, high levels of active vitamin D metabolites (25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3) and low levels of inactivated vitamin D (24,25-dihydroxyvitamin D3). A recent study screening patients with known calcium nephrolithiasis for CYP24A1 mutations did not identify any biallelic variants in a cohort of 166 patients, suggesting CYP24A1 mutations are a rare cause of idiopathic nephrolithiasis [8]. However, given our increased understanding of this phenotype, it is imperative that recognition of the typical biochemical pattern (suppressed PTH, hypercalcaemia, hypercalciuria) in any patients with nephrolithiasis prompts investigation for CYP24A1 mutations [4, 6, 8]. Establishing a molecular diagnosis in this small cohort of patients can facilitate correct treatment and lifestyle modification (Table 1) [9].

Clinical featuresBiochemical profile
Idiopathic infantile hypercalcaemia:
  • Vomiting

  • Dehydration

  • Failure to thrive

  • Fever

  • Adult presentation:

  • Nephrolithiasis

  • Nephrocalcinosis

  • ↑ 25-hydroxyvitamin D3

  • ↑ 1,25-dihydroxyvitamin D3

  • ↓ 24,25-dihydroxyvitamin D3

  • ↑ or high normal serum calcium

  • ↑ urine calcium

  • ↓ parathyroid hormone

Table 1.

Key features of CYP24A1 mutation phenotypes.

2.1.3. Investigation

In patients with CYP24A1 mutations, an elevation in total vitamin D levels is typically seen. In particular, 1,25-dihydroxyvitamin D3 levels are increased, but this assay is not routinely performed in many laboratories. Conversely, serum 24,24-dihydroxyvitamin-D3 levels are sometimes low or undetectable in patients with CYP24A1 mutations. A blood test that calculates the ratio between vitamin D metabolites could be utilised in future clinical practice as a screening tool for CYP24A1 mutations in those patients presenting with a typical biochemical profile. In the first study of this, Molin et al. used liquid chromatography–tandem mass spectrometry to calculate the ratio of active to inactive vitamin D metabolites: Molar ratio (R) of 25-hydroxyvitamin-D3: 24,25-dihydroxyvitamin D3. A large increase in the ratio of active to inactive vitamin D metabolites, usually R > 80, was demonstrated in subjects who had biallelic mutations resulting in loss of function of CYP24A1. Importantly, through use of a ratio calculation, this test can avoid misleading results in patients who might have low 24,24-dihydroxyvitamin-D3 levels due to vitamin D deficiency [6].

2.2. CYP24A1 variants

Several different loss-of-function mutations have now been identified within the CYP24A1 gene. The mutations are reported to be inherited in an autosomal recessive pattern, although it is not yet clear whether partial penetrance or environmental factors may alter manifestation of a recognised phenotype. One study showed individuals with biallelic mutations presented with the clinically recognised phenotype and that heterozygous carriers were not sufficient to manifest clinical disease. However, it was hypothesised that infants with haploinsufficiency/heterozygous variants may be more sensitive to hypercalcaemia during childhood while the kidney is still developing, and this could become relevant in considering additional vitamin D supplementation which might overwhelm the 1,25-hydroxyvitamin-D3-24-hydroxylase enzyme pathway in this cohort (Table 2) [4, 6].

Year mutation  reportedAge at presentationPhenotypeCYP24A1 mutation Reference
20116 monthsIIHA475fsX490 homozygoteSchlingmann et al. [2]
20116 monthsIIHdelE143 and E151XSchlingmann et al. [2]
2011AsymptomaticIdentified on family
screening
delE143 and E151XSchlingmann et al. [2]
20118 monthsIIHL409S and R396WSchlingmann et al. [2]
2011AsymptomaticIdentified on family
screening
L409S and R396WSchlingmann et al. [2]
201111 monthsIIHdelE143 and R159QSchlingmann et al. [2]
20117 monthsIIHE322K and R396WSchlingmann et al. [2]
20113.5 monthsIIHE322K and R396WSchlingmann et al. [2]
20117 weeksIIHR396W homozygoteSchlingmann et al. [2]
20115 weeksIIHComplex deletionSchlingmann et al. [2]
201210 monthsIIHHomozygous delE143Dauber et al. [10]
201244 yearsIntermittent
hypercalcaemia,
hypercalciuria,
nephrolithiasis
2 canonical intron-exon
splice junction mutations
(IVS5 +1G>A and IVS6 -2A>G)
Tebben et al. [11]
20134 monthsIIHHomozygous R396WFencl et al. [12]
20139 yearsNephrocalcinosis, nephrolithiasisHomozygous delE143Dinour et al. [4]
201319 yearsNephrolithiasis, nephrocalcinosis, bladder calcificationCompound
heterozygous
L409S and W268X
Dinour et al. [4]
201313 yearsNephrolithiasis, nephrocalcinosis, hypercalcaemia, hypercalciuriaCompound
heterozygous
L409S and W268X
Dinour et al. [4]
20139 yearsNephrocalcinosis, hypercalciuriaCompound
heterozygous
delE143 and L148P
Nesterova et al. [5]
201325 yearsNephrolithiasis, hypercalcaemia, hypercalciuriaCompound
heterozygous
delE143 and L409S
Nesterova et al. [5]
20134.5 monthsIIHHomozygous R396WSkalova et al. [13]
20133 monthsIIH followed by adult presentation with nephrocalcinosis, CKD, hypercalcaemia and hypercalciuriaHomozygous W210RMeusburger et al. [14]
2014~20 yearsNephrolithiasis, hypercalcaemia, hypercalciuriaHomozygous delE143Jacobs et al. [15]
201510 yearsNephrolithiasis, hypercalcaemia, hypercalciuriaHomozygous delE143Sayers et al. [7]
201545 yearsNephrocalcinosis, hypercalcaemia, hypercalciuriaCompound
heterozygous
G469Afs*22 and P21R
Figueres et al. [19]
201532 yearsNephrolithiasis, nephrocalcinosis, hypercalcaemia, hypercalciuriaCompound
heterozygous L409S and R157W
Figueres et al. [19]
201528 daysIIHCompound
heterozygous
R157W and M374T
Figueres et al. [19]
20152 monthsIIHCompound
heterozygous
L409S and R396W
Figueres et al. [19]
20156 monthsIIHHomozygous L409SFigueres et al. [19]
20152 monthsIIHCompound
heterozygous
R396W and R396G
Figueres et al. [19]
20156 monthsIIHCompound
heterozygous
delE143 and L409S
Figueres et al. [19]
20151 dayHypercalcaemia, apnoeaHeterozygous M374TMolin et al. [6]
20153 daysInfection, hypercalcaemia,
suppressed PTH
Heterozygous M374TMolin et al. [6]
201511 daysPrematurity,
hypercalcaemia,
suppressed PTH
Heterozygous G322AMolin et al. [6]
20154 daysPrematurity, hypercalcaemia,
suppressed PTH
Heterozygous R439CMolin et al. [6]
201513 daysSmall for gestational age,
hypercalcaemia, suppressed PTH
Heterozygous M374TMolin et al. [6]
201524 yearsHypercalcaemia, suppressed
PTH,
nephrocalcinosis,
CKD
Homozygous delE143Jobst-Schwan et al. [3]
2015AsymptomaticIdentified on family
screening
Homozygous delE143Jobst-Schwan et al. [3]
201526 yearsNephrocalcinosis, hypercalcaemia, hypercalciuriaHomozygous delE143Tray et al. [16]
201521 yearsNephrocalcinosis, nephrolithiasis, hypercalcaemiaHeterozygous delE143 and R396WTray et al. [16]
20155 monthsIIHCompound
heterozygous
R396W and W134G
Dinour et al. [17]
20159 monthsIIHCompound
heterozygous
G315X and W134G
Dinour et al. [17]
20155 monthsIIHHomozygous delE143Dinour et al. [17]
201535 yearsNephrolithiasis, nephrocalcinosis
and hypercalcaemia
during
pregnancy
Homozygous delE143Dinour et al. [17]

Table 2.

Identified mutations in CYP24A1.

CKD, chronic kidney disease; IIH, idiopathic infantile hypercalcaemia; PTH, parathyroid hormone.

2.3. Treatment

CYP24A1 mutations lead to calcium stone formation, and conventional treatments for calcium stones are recommended. These would include maintaining a high fluid intake and avoiding excess dietary sodium. Specific measures would include avoiding dietary vitamin D supplements (in foods and drinks) and avoidance of excessive sunlight exposure [7]. Ketoconazole was first demonstrated as an effective treatment for reducing the effects of vitamin D toxicity in patients with CYP24A1 mutations. As a non-specific P450 enzyme inhibitor ketoconazole inhibits the enzyme catalysing production of 1,25-dihydroxyvitamin D3, (1α-hydroxylase), thereby decreasing levels of active vitamin D3. However, CYP24A1-deficient individuals require lifelong treatment as they will always lack the enzyme to inactivate vitamin D, and the side-effect profile of ketoconazole, which includes hepatotoxicity, hypogonadism and adrenal insufficiency, makes it unsuitable for this purpose [4]. More recently, low-dose fluconazole, also acting as a P450 enzyme inhibitor, has been shown to reduce serum calcium levels and urinary calcium excretion in a patient with CYP24A1 mutation. It is likely that this drug, alongside lifestyle modifications such as avoiding excess sun exposure and following a low calcium and oxalate diet, will become the main treatment offered to patients diagnosed with CYP24A1 mutations (Figure 2) [7, 18, 19].

Figure 2.

Chemical structures of ketoconazole, an imidazole antifungal agent, and fluconazole, a triazole antifungal agent. Azole agents are cytochrome inhibitors primarily used as antifungal agents. They are heterocyclic ring compounds and are generally classified as either imidazoles (e.g. ketoconazole) or triazoles (e.g. fluconazole), containing two or three nitrogen atoms, respectively, in the azole ring. They exhibit their antifungal action through inhibition of lanosterol 14-α demethylase, a cytochrome P450 enzyme important for the synthesis of a fungal plasma membrane constituent.

2.4. Evidence for genetic heterogeneity of idiopathic infantile hypercalcaemia

Since the discovery of CYP24A1 mutations underlying idiopathic infantile hypercalcaemia (IIH) in 2011, a cohort of IIH patients has been identified without CYP24A1 mutations. In 2015, a new loss-of-function mutation in SLC34A1, which encodes the renal sodium–phosphate cotransporter 2A (NaPi-IIa), was recognised in this group [20]. These patients presented with a classical IIH phenotype, with symptoms of hypercalcaemia. Importantly, however, their symptoms did not resolve with removal of vitamin D supplementation. Instead, their hypercalcaemia corrected rapidly after commencing phosphate replacement, highlighting the different mechanism driving the hypercalcaemia. In patients with SLC34A1 mutations, renal phosphate wasting leads of inappropriately high levels of 1,25-dihydroxyvitamin-D3, which in turn causes hypercalcaemia. It is crucial to distinguish between patients carrying mutations in CYP24A1 versus SLC43A1, as different intervention is required to successfully treat their hypercalcaemia [20]. As SLC34A1 mutations have also been identified as a cause of nephrolithiasis, there is overlap between SLC34A1 and CYP24A1 mutation phenotypes in both paediatric and adult presentations [21].

3. Conclusions

Overall, CYP24A1 mutations are rare and account for a small proportion of symptomatic hypercalcaemia or nephrolithiasis cases. However, a greater awareness of their phenotypes will increase clinical suspicion in patients presenting with a typical biochemical profile. Testing for mutations in CYP24A1 can establish a definitive diagnosis, avoiding protracted further investigations and allowing treatment to commence. Alongside dietary and lifestyle advice, aimed at minimising vitamin D intake, fluconazole is proving a promising lifelong treatment to prevent effects of vitamin D toxicity.

Acknowledgments

JAS is supported by the Northern Counties Kidney Research Fund.

© 2017 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Fay Joanne Hill and John A. Sayer (April 12th 2017). Clinical and Biochemical Features of Patients with CYP24A1 Mutations, A Critical Evaluation of Vitamin D - Basic Overview, Sivakumar Gowder, IntechOpen, DOI: 10.5772/64503. Available from:

chapter statistics

860total chapter downloads

2Crossref citations

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Synthesis of Low Abundant Vitamin D Metabolites and Assaying Their Distribution in Human Serum by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) as a New Tool for Diagnosis and Risk Prediction of Vitamin DRelated Diseases

By Lars Kattner and Dietrich A. Volmer

Related Book

First chapter

Vitamin D and Cardiovascular Diseases

By Claudia Lama von Buchwald and Seth I. Sokol

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us